pimavanserin   Click here for help

GtoPdb Ligand ID: 8423

Synonyms: ACP 103 | ACP-103 | Nuplazid (proposed trade name)
Approved drug
pimavanserin is an approved drug (FDA (2016))
Compound class: Synthetic organic
Comment: Pimavanserin is an inverse agonist of the serotonin 5-HT2A receptor [4]. Pharmaceutical formulations contain pimavanserin tartrate (PubChem CID 67017013) .
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: pimavanserin

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 4
Hydrogen bond donors 1
Rotatable bonds 10
Topological polar surface area 44.81
Molecular weight 427.26
XLogP 4.46
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CC(COc1ccc(cc1)CNC(=O)N(C1CCN(CC1)C)Cc1ccc(cc1)F)C
Isomeric SMILES CC(COc1ccc(cc1)CNC(=O)N(C1CCN(CC1)C)Cc1ccc(cc1)F)C
InChI InChI=1S/C25H34FN3O2/c1-19(2)18-31-24-10-6-20(7-11-24)16-27-25(30)29(23-12-14-28(3)15-13-23)17-21-4-8-22(26)9-5-21/h4-11,19,23H,12-18H2,1-3H3,(H,27,30)
InChI Key RKEWSXXUOLRFBX-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
In 2014 US FDA granted breakthrough therapy status for pimavanserin as a potential treatment for Parkinson's disease psychosis, following the completion of Phase 2I clinical trials for this indication. A Phase 2 trial administering pimavanserin as an adjunctive treatment for schizophrenia (in combination with antipsychotic medications such as risperidone and haloperidol) has also been completed. A further Phase 2 trial in patients with Alzheimer's disease psychosis is underway.
In November 2015, the US FDA confirmed that the New Drug Application (NDA) for Nuplazid® branded pimavanserin will be considered under it's 'Priority Review' process, to expedite its approval as a treatment of psychosis associated with Parkinson's disease, a condition for which there was no previous FDA-approved therapy. This Priority Review resulted in a 2016 approval for treating hallucinations and delusions associated with Parkinson's disease.